1,3,5,8-Tetrahydroxyxanthone (Desmethylbellidifolin) attenuates lipopolysaccharide-induced nitric oxide release and proinflammatory cytokine expression in RAW264.7 cells.
1,3,5,8-Tetrahydroxyxanthone (Desmethylbellidifolin; orally; 5, 10, 20 mg/kg; 12 days) can inhibit trinitrobenzenesulfonic acid (TNBS)-induced ulcerative colitis (UC), reducing inflammatory response and alleviate colon muscle spasm.